Tag Archives: Pfizer

Pharma's Influence on the Super Committee: Is Cash Really King?

By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
Posted in Strategy, healthcare, leadership | Also tagged , , , , , | 1 Comment

Planning Beyond the Petri Dish: A Pfizer Case Study

By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D | Also tagged , , , , , , | Leave a comment

Study Points to Dramatic Drop In R&D Expenditure

By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment

The High Cost of Staying Lean

By William Looney | Published: April 13, 2011
It’s annual meeting time for Big Pharma — and trimming the fat to deliver more bacon to shareholders is the C suite’s preferred plat du jour. But taking costs out of the business can carry a staggering special supplement charge to the menu, with far more at stake than the economizing equivalent of that McDonald’s [...]
Posted in Strategy | Also tagged , , , , | Leave a comment

Pfizer to Acquire King Pharmaceuticals

By Jennifer Ringler | Published: October 12, 2010
The merger, announced on Tuesday, will cost Pfizer $3.6 billion. Pfizer and King Pharmaceuticals announced on Tuesday they have entered into a definitive friendly merger agreement. Under the terms, Pfizer will acquire King, a diversified specialty pharmaceutical company based in Tennessee, for $3.6 billion in cash, or $14.25 per share. The company emphasized the deal is not [...]
Posted in Deals | Also tagged | Leave a comment